mage-3.a1 peptide
Vaccineexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2005 (NCT00145145)
Timeline
Indications
Mechanism of action
- Melanoma-associated antigen 3Immunity, active
MAGEA3 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- mage-3.a1 peptide
- mage-a1 peptide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01191034 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2010 | Université catholique de Louvain |
| NCT00373217 | Phase 2 | Feb 1, 2008 | National Cancer Institute (NCI), University of Virginia |
| NCT00145145 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2005 | Ludwig Institute for Cancer Research |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ludwig Institute for Cancer Research | Academic/Hospital | 1 | 1 | 1 | 2005 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2008 |
| Université catholique de Louvain | Academic/Hospital | 1 | 1 | 1 | 2010 |
| University of Virginia | Academic/Hospital | 1 | 1 | 1 | 2008 |
4 organizations
Page 1 / 1